In interpreting and aggregating data in published reports, readers and authors must be aware that some data loss and transformation are inevitable in the process (figure 1). Kamp and colleagues recently examined the beneficial and adverse event (AE) profiles of tricyclic antidepressants in a systematic review of available evidence from randomised controlled trials. The authors identified 103 trials randomising 10,590 participants, concluding that in the short term these medications may reduce depressive symptoms (mean difference on the 17-item Hamilton Rating Scale for Depression of −3.77, 95% CIs −5.91 to −1.63; 17 studies; low certainty of evidence) and increase the chances of ‘serious AEs’ (SAEs) (OR 2.78, 95% CI 2.18 to 3.55; 35 trials; very low certainty of evidence) compared with placebo.2

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the European Medicines Agency, and the Food and Drug Administration define AEs as ‘any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment’. An AE is considered serious and thus cause regulatory implications when it ‘results in death, is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect’, with each criterion being evaluated at a patient and event level.3−5 For instance, ‘the term life-threatening in the definition of serious refers to an event in which the patient was at risk of death at the time of the event, rather than an event which hypothetically might have caused death if it were more severe’.

In their systematic review, Kamp and colleagues applied their own judgement in categorising specific AEs as non-serious or serious, usually consisting in a worst-case scenario when severity details were considered inadequately reported by the original authors.2 For instance, ‘taste alteration/perversion’ was considered an SAE occurring in 26 out of 677 participants enrolled in four studies (figure S18, Kamp and colleagues).2 Moreover, they had access only to aggregate data to evaluate the seriousness of AEs. Not all the AEs that, on average, are associated to additional care are SAEs at an individual level (eg, not all individuals experiencing blurred vision will require hospitalisation or will be in a life-threatening condition; figure S16, Kamp and colleagues).2 The widely accepted definition of SAE appeared in the mid-1990s.3 As 11 out of the 103 studies contributing to the primary outcomes were published after 2000, it is expected that the original investigators did not report the exact numbers of SAEs as currently understood.

When observed clinical information (source event) is translated into source data at the collection site, how data are measured will set implications downstream (figure 1). This is where data flattening can occur, a process where data are simplified via reduction of their number of dimensions (eg, instead of measuring a variable as continuous, it is categorised into an ordinal variable or dichotomised). This may happen voluntarily to reduce the amount of information stored or to avoid collecting data that are considered not relevant. After data are flattened, restoration of lost information is not possible, with imputation being the only possible solution.6 External researchers are limited to flattened aggregate data reported by original authors (published data). When seriousness of AEs is not clearly reported, researchers can (1) renounce to use that data, (2) consider all the events as non-serious (flooring, best-case scenario) or (3) consider all as serious (ceiling) based on the average outcome (ie, a specific AE usually results in hospitalisation) or the worst outcome (ie, a specific AE may worsen and result in hospitalisation, worst-case scenario). Any of these assumptions might generate deviations from the truth and should be carefully examined and discussed.7

It is truly important to understand the absolute and relative frequencies of AEs and potential harms associated with medical interventions.8 We applaud the authors’ efforts towards this goal. Access to individual participant data can overcome reporting bias but, to limit information loss, what data should be collected and in which format should follow rigorous criteria widely established across the regulatory and scientific communities (standardisation). This is increasingly important given their emerging role in shared decision-making processes and patient decision aids aimed at identifying who may be at higher risk of experiencing harms.9

For the very same reason, it is essential to rely on a lingua franca of research on medical interventions when referring to aggregate data on harms.9 Additionally, uniformity on characterisation and format of safety data would translate into dataset harmonisation across studies, countries and sponsors, introducing several benefits10: federated analyses would bypass data sharing agreement while preserving individual patient’s privacy, increasing access to data and maximising transparency11; linking harmonised data to pharmacovigilance repositories...
would be facilitated, allowing real-time contribution of multiple data sources into a synchronous environment.

Twitter Edoardo Giuseppe Ostinelli @EGOstinelli and Toshi A Furukawa @Toshi_FRKW

Contributors EGO: Conceptualisation; writing—original draft; visualisation. TAF: Conceptualisation; writing—review and editing.

Funding EGO is supported by the National Institute for Health and Care Research (NIHR) Research Professorship (grant RP-2017-08-ST2-006), by the National Institute for Health Research (NIHR) Applied Research Collaboration Oxford and Thames Valley (ARC OxTV) at Oxford Health NHS Foundation Trust, by the NIHR Oxford Health Clinical Research Facility, by the NIHR Oxford Health Biomedical Research Centre (grant BRC-1511-20005) and by the Brasenose College Senior Hulme scholarship. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR or the Department of Health and Social Care.

Competing interests EGO received research and consultancy fees from Angelini Pharma. TAF reports personal fees from Boehringer-Ingelheim, DT Axis, Kyoto University Original, Shionogi and SONY, and a grant from Shionogi, outside the submitted work; in addition, TAF has patents 2020-548587 and 2022-082495 pending, and intellectual properties for Kokoro-app licensed to Mitsubishi-Tanabe.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs Edoardo Giuseppe Ostinelli http://orcid.org/0000-0002-8717-0832

Toshi A Furukawa http://orcid.org/0000-0003-2159-3776

REFERENCES